Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Semaglutide news
All news on
Semaglutide
(also known as
Wegovy
and
Ozempic
): plants, production capacities, investments and involved companies.
3 June 2026
Novo Nordisk launches Wegovy pill in UAE
Oral semaglutide tablet now available in UAE for weight management; shows ~17% mean weight loss in trials and is approved to reduce certain cardiovascular risks.
1 June 2026
Roche to present obesity‑portfolio data at ADA 2026
Phase II data show enicepatide and petrelintide yield meaningful weight loss with good safety/tolerability. Both advance toward Phase III; a Phase II combo trial starts mid‑2026
28 May 2026
Aptar Pharma files patents and reports preclinical proof‑of‑concept for intranasal and pulmonary GLP‑1 delivery
Published three international patent applications for nasal/pulmonary GLP‑1 formulations (spray‑dried/powder). Preclinical semaglutide PK shows up to 10× Cmax vs oral; ongoing biologics delivery work.
22 May 2026
Novo Nordisk: CHMP recommends Wegovy pill (oral semaglutide), the first oral GLP‑1, for EU approval
Oral semaglutide showed 16.6% mean weight loss (OASIS4, adherent); SELECT data added to label for CV risk reduction; no drug-drug restrictions; planned launch outside US H2 2026.
19 May 2026
Novo Nordisk: Semaglutide shows hepatic safety and efficacy in MASH
ESSENCE subgroup analyses (menopause, Japanese) and real-world data show broad benefit across populations, highlight severe underdiagnosis, reduced quality of life and rising healthcare costs
13 May 2026
Novo Nordisk: Wegovy pill yields 21.6% weight loss in early responders and doubles mobility improvement
Nearly 29% were early responders (≥10% by 16w), averaging 13.2% loss at 16w; non-responders still lost 11.5% by wk64. Overall mean 17% vs 2.7% placebo. Outperformed orforglipron; GI AEs mostly mild.
Who will be producing Semaglutide in the future?
Find out with
chemXplore Alpha
Learn more
12 May 2026
Lilly: Foundayo and reduced-dose Zepbound maintain weight loss after switching from high-dose injectables
Two late-phase trials: switching from high-dose injectable incretins to an oral GLP-1 or reducing injectable dose preserved most prior weight loss at 1 year; safety matched prior Phase 3
12 May 2026
Novo Nordisk: Wegovy cuts weight and reduces cardiovascular and migraine risk across menopausal stages
Trials and real‑world data: semaglutide gave 19.7–22.6% weight loss, 15–17.5% waist reduction, ~42% MACE risk reduction in perimenopause, 42–45% lower migraine and 25% lower depression risk
12 May 2026
Novo Nordisk: Wegovy 7.2 mg yields ~28% weight loss in early responders
STEP UP trial: early responders (≥15% at 24w) sustained major weight loss at 72w; higher dose reached goals faster than 2.4 mg; 84% of lost weight was fat and muscle function preserved.
1 May 2026
Novo Nordisk launches Ozempic pill — FDA‑approved oral semaglutide for adults with type 2 diabetes
Tablets (1.5, 4, 9 mg) debut in US May 4. Reformulated from Rybelsus, available at 70,000+ pharmacies; insurance from $25; self-pay $149/199/299/month. Approved to reduce cardiovascular events
28 April 2026
Novo Nordisk to present Wegovy and next‑generation obesity data at ECO 2026
Presenting 52 abstracts at ECO: data on semaglutide (injectable and oral), higher‑dose 7.2 mg, CagriSema combo, menopause effects, CV risk, weight‑loss timelines and real‑world outcomes.
23 April 2026
Novo Nordisk: Oral semaglutide lowers HbA1c in adolescents with type 2 diabetes
PIONEER TEENS phase 3a: first oral GLP‑1 RA trial in 10–17‑year-olds with type 2 diabetes (n=132). 52‑week, placebo‑controlled; safety matched adult trials; regulatory filings planned H2.
9 April 2026
Novo Nordisk: Wegovy injection approved for up to 48-hour controlled‑temperature delivery in the EU
EMA change reduces last‑mile cold‑chain needs, lowering packaging/transport costs, enabling discrete home and online dispensing; SmPC updated for healthcare providers; patient leaflet unchanged.
2 April 2026
Novo Nordisk: Wegovy pill shows greater weight loss and lower discontinuation vs orforglipron in indirect comparison
Indirect comparison (ORION) found oral semaglutide 25 mg led to ~3% greater weight loss vs orforglipron; orforglipron had higher discontinuation for AEs (esp. GI); 84% preferred semaglutide-like profile.
25 March 2026
Novo Nordisk: UBT251 reduced HbA1c up to 2.16% at 24 weeks in Chinese Phase 2 T2D trial
Triple-agonist UBT251 (GLP-1/GIP/glucagon) induced up to 9.8% weight loss, improved BP and lipids vs placebo/semaglutide. Safety consistent with triple-G class; global phase-2 and China phase-3 planned
19 March 2026
FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial
Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
19 March 2026
Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss
STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
9 March 2026
Novo Nordisk Partners with Hims & Hers to Expand Access to Semaglutide in the US
Hims & Hers will offer FDA-approved semaglutide medicines at self-pay prices, shifting focus from compounded GLP-1 offerings to increase patient access.
23 February 2026
Novo Nordisk: CagriSema Shows 23% Weight Loss in Trial, Misses Primary Endpoint
CagriSema achieved 23% weight loss in 84 weeks but didn't match tirzepatide. Further trials will explore higher doses. Safe profile with mild gastrointestinal effects.
17 February 2026
Novo Nordisk: EU Approves Higher Wegovy® Dose for Obesity, 21% Average Weight Loss
The EU approved a 7.2 mg Wegovy® dose for obesity. In studies, participants lost 21% body weight on average. Common side effects: nausea, diarrhea, vomiting, and dysaesthesia.
9 February 2026
Novo Nordisk Sues Hims & Hers Over Unapproved Semaglutide Products
Novo Nordisk seeks to stop Hims from selling unapproved semaglutide, citing patient safety risks and patent infringement.
4 February 2026
Novo Nordisk Launches Ozempic® Pill in US by Q2 2026
FDA approves Ozempic® tablets for type 2 diabetes, offering enhanced bioavailability. Launch set for Q2 2026.
3 February 2026
Novo Nordisk Reports 6% Sales Growth in DKK, 10% at CER for 2025
Operating profit fell 1% in DKK, rose 6% at CER. US FDA approved oral GLP-1 for obesity. 2026 sales growth expected to decline due to pricing and competition. New treatments in pipeline.
3 February 2026
Novo Nordisk 2025 Financial Report
Sales rose 10% at CER, operating profit up 6%. US FDA approved oral GLP-1. 2026 outlook: sales/profit growth -5% to -13% at CER. New share repurchase program announced.
2 February 2026
Novo Nordisk Announces REIMAGINE 2 Trial Results
CagriSema showed superior HbA1c reduction and weight loss over semaglutide in a 68-week trial with type 2 diabetes patients inadequately controlled with metformin.
31 December 2025
Novo Nordisk Wins Semaglutide Patent Case in China
China's Supreme Court upholds the semaglutide patent, boosting confidence in foreign medical innovation and supporting sustainable development in China.
22 December 2025
FDA Approves Novo Nordisk's Oral Wegovy for Adult Weight Loss
FDA approves Wegovy pill, the first oral GLP-1 for weight loss, showing ~17% loss in trials. Available January at $149/month, it also reduces cardiovascular risks in adults with obesity.
22 December 2025
Novo Nordisk: FDA Approves Wegovy® Oral Pill for Weight Management
Wegovy® pill, an oral GLP-1, shows 16.6% weight loss in trials. Launch expected in the US by January 2026. Approval based on OASIS and SELECT trials.
18 December 2025
Lilly's Orforglipron Maintains Weight Loss in Phase 3 Trial
Orforglipron met primary and key secondary endpoints for weight maintenance at 52 weeks post-weight loss on Wegovy. FDA submission for obesity treatment is underway.
18 December 2025
Novo Nordisk Seeks FDA Approval for CagriSema, a Weekly Obesity Treatment
CagriSema, combining cagrilintide and semaglutide, shows 23% weight loss in trials. If approved, it offers a new obesity treatment option.
Next →
